ABSTRACT The bronchodilatation achieved by the f2 agonist terbutaline sulphate given as nebulised aerosol from different devices has been measured in seven patients with mild asthma (mean FEV, 76% predicted) over two hours after inhalation. The subjects were studied on four occasions. On three visits they received 2.5 mg terbutaline delivered from three different types of nebuliser, selected on the basis of the size distribution of the aerosols generated; and on a fourth (control) visit no aerosol was given. The size distributions of the aerosols expressed in terms of their mass median diameter (MMD) were: A: MMD 1.8 pm; B: 4.6 ,um; C: 10.3 pm. The aerosols were given under controlled conditions of respiratory rate and tidal volume to minimise intertreatment variation.
Aerosol size is the most important factor determining the site of aerosol deposition within the respiratory tract.' During inhalation aerosols are filtered out from the airstream according to their size. Few particles larger than 10 pm pass the larynx.2 Particles of 5-10 pm have a high probability of being deposited in the large airways, particularly at bifurcations. Particles smaller than 5 pm may penetrate deeper into the lung but less so in the presence of airways obstruction, when particles smaller than 2 pm may be required. Aerosol particles smaller than 0.5 pm, however, have a high airborne stability and may be exhaled without being deposited at all. 3 Nebulisers are frequently used to deliver bronchodilator aerosols, and previous work has shown that there is considerable variation between makes and driving conditions that affects the size of the particles released.4 Given that adrenoreceptors may exist in higher concentrations in the small airways,5 6 we Effect of aerosol particle size on bronchodilatation with nebulised terbutaline in asthmatic subjects with an average smoking history of 23 The subjects were seated with their nostrils occluded by a noseclip. The aerosols were inhaled through a mouthpiece directly from the nebuliser under strictly controlled conditions to minimise intertreatment variation. The subjects synchronised their breathing to an audible signal generated by an electronic device, which facilitated a breathing pattern of 14 breaths a minute with inspiration lasting one third of the respiratory cycle. In addition, they inhaled a fixed volume (700 ml) with each breath regulated by the use of Voldyne Volumetric Exerciser (Cheeseborough Pond Ltd), thereby ensuring a reproducible inhalation pattern between aerosol studies.
The volume of aerosol produced during nebulisation was determined by weighing the device before and after, and the duration of nebulisation itself was timed with a stopwatch.
STATISTICS
Non-parametric statistics were applied to the experimental results. These were the Friedman analyses of variance and the Wilcoxon rank sum test for paired and unpaired data.7
Results
There was no significant difference between the mean (SE) volumes of aerosol generated by the three nebulisers: Aerosol A 1.84 (0.12) ml; aerosol B 1.70 (0.03) ml; aerosol C 1.88 (0.10) ml. The duration of nebulisation, however, varied significantly between the three studies as a result of the flow rates used to drive figure 1 ; all were significantly better after aerosol Time after aerosol inhalation (min) Figure 2 shows the flow-volume curves obtained in one subject one hour after the three aerosols and also at one hour in the control run. The figure shows a gradation in improvement in Vmax50 and Vmax25 with decreasing aerosol size (A > B > C > control).
For the group of seven subjects taken as a whole, figure 3 shows the mean (SE) improvements in Vmax50 over baseline values throughout the two hour observation period. Aerosol A achieved better bronchodilatation than either aerosol B or aerosol C throughout, and this difference was significant (p < 0.05) during the entire two hours when aerosol A was compared with C and at 30 and 90 minutes when it was compared with aerosol B.
There was no significant difference between aerosols B and C but the values obtained with all three were consistently better than control values (p < 0.05). Figure 4 shows the improvements in Vmax25 during the two hour observation period. Aerosol There was no significant difference between the pulse rates obtained during the hours after inhalation of any of the aerosols and the control pulse rates (table 2) .
Discussion
This study set out to compare the efficacies of three nebulised aerosols of the bronchodilator terbutaline. Although the three aerosols were generated by three different makes of nebuliser, because the volume of aerosol and inhalation mode were kept constant between treatments we may reasonably assume that any observed differences were the result of differences in the quality of the aerosols themselves. The aerosols were selected for differences in their size distributions that would influence the site and amount of deposition in the lung. Aerosol A, with an MMD of 1.8 gm, would be expected to deposit more in the lung than aerosols B or C. We believe that the results offer convincing evidence that the bronchodilator efficacy of terbutaline is directly affected by the aerosol size.
Surprisingly little work has been carried out to examine whether there is any therapeutic advantage in the use of bronchodilator aerosols of small particle size. As the distribution of receptors within the lung is elucidated it becomes possible to "target" an aerosol towards a particular region of the respiratory tract. Krieger8 and Rees and Clark,9 using pressurised aerosols from metered dose inhalers, were In the presence of airways obstruction aerosols of a particular particle size penetrate less deeply. To achieve the same depth of penetration particle size has to be reduced.'6 It is therefore possible that an aerosol with an MMD of 5 um or greater may be deposited more and more centrally with increasing severity of airways obstruction and ultimately fail to penetrate the airways at all; in such circumstances an aerosol with smaller particles might still penetrate the airways and be effective. This possibility has not hitherto been considered and it could account for the failure of nebuliser treatment that may occur in acute severe asthma.
